EAN 2022 | Interim results of SC foslevodopa/foscarbidopa in Parkinson’s disease

Foslevodopa/foscarbidopa is a new formulation of levodopa/carbidopa prodrugs delivered through continuous subcutaneous (SC) infusion. K. Ray-Chaudhuri, MD, DSc, FRCP, FEAN, King’s College London, London, UK, shares the six-month interim results of the Phase III, open-label, single-arm, multicenter study (NCT03781167) of foslevodopa/foscarbidopa in Parkinson’s disease patients whose motor and nonmotor symptoms were inadequately controlled by their current treatment. Data showed a sustained improvement in motor function: improved “on” time without troublesome dyskinesia. Importantly, there was a strong signal of improvement in the sleep scores (PDSS), activities of daily living, and quality of life. This interview took place at the European Academy of Neurology (EAN) 2022 Congress in Vienna, Austria.